Pharmacy Grand Rounds

Let's Get Ready to CAR-T: Management of Immunotherapy Toxicities

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Immune checkpoint inhibitors and CAR T-cell therapy have revolutionized the treatment of many types of cancers. Unfortunately, these new therapies can cause detrimental adverse effects. This presentation will review the mechanism of these therapies and the adverse effects. Management of immunotherapy and CAR-T cell therapy toxicities will be reviewed.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe the mechanism of immune checkpoint inhibitor and CAR T-cell therapy toxicities.
2. Review the most common types of toxicities and risk factors associated with immunotherapy treatments.
3. Discuss literature and guideline recommendations for the management of immunotherapy toxicities.

Session Announcement

Session Slides

FACULTY INFORMATION

Victoria R. Milano, PharmD
PGY2 Critical Care Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Victoria earned a Doctor of Pharmacy degree from the University of Wyoming in Laramie, WY and completed PGY1 Pharmacy Residency at Mayo Clinic Hospital—Rochester in 2019. She is the current PGY2 Critical Care Pharmacy Resident at Mayo Clinic Hospital—Rochester and has practice interests in critical care and infectious diseases.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Victoria R. Milano, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Cyclophosphamide
    • Infliximab
    • Methylprednisolone
    • Mycophenolate
    • Prednisone
    • Tacrolimus
    • Tocilizumab

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS